CytomX Therapeutics, Inc.
CTMXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
3dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CTMX Earnings Report
EPS Est: $-0.11 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How CTMX's past catalysts played out
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CytomX Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in CytomX Therapeutics, Inc.'s (CTMX) pipeline across Phase 2. Its lead program is CX-2009 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CytomX Therapeutics, Inc.'s next FDA catalyst?→
CytomX Therapeutics, Inc.'s (CTMX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CTMX biotech catalysts?→
Add CTMX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CytomX Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.